1. Praxis is presenting at three upcoming investor conferences this month. 2. Key presentations scheduled for September 9, 10, and 18, 2025. 3. Praxis focuses on therapies for central nervous system disorders. 4. The company may engage with potential investors during these events.
Increased visibility at investor conferences may boost investor confidence and interest. Historically, similar announcements have positively impacted stock prices.
Upcoming presentations can lead to increased investor engagement, affecting stock performance short-term.
The immediate weeks surrounding the conferences are likely to see heightened market activity. Long-term effects depend on subsequent performance and announcements.
BOSTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that Praxis' management will be attending and presenting in three upcoming investor conferences:
The Company will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.
A replay of the webcasted event will also be available through the "Events & Presentations" page under the "Investors + Media" section of the company's website for 90 days.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576
